A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects

NCT01913028 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: MEDI9929
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]